• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Theratechnologies Inc (NQ: THTX )

    1.300 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EDT, Jun 25, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 61
    Open 1.300
    Bid (Size) 1.060 (3)
    Ask (Size) 1.370 (1)
    Prev. Close 1.300
    Today's Range 1.300 - 1.300
    52wk Range 0.8800 - 3.920
    Shares Outstanding 77,013,411
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
    From Theratechnologies
    Via GlobeNewswire

    Performance

    YTD
    -23.08%
    -23.08%
    1 Month
    +3.17%
    +3.17%
    3 Month
    -7.80%
    -7.80%
    6 Month
    -18.24%
    -18.24%
    1 Year
    -63.89%
    -63.89%

    More News

    Read More
    Theratechnologies Reports on its Annual Meeting of Shareholders
    From Theratechnologies
    Via GlobeNewswire
    Earnings Scheduled For February 21, 2024
    Via Benzinga
    Theratechnologies Earnings Preview
    Via Benzinga
    Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    From Theratechnologies
    Via GlobeNewswire
    THTX Stock Earnings: Theratechnologies Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
    From Theratechnologies
    Via GlobeNewswire
    Earnings Scheduled For April 10, 2024
    Via Benzinga
    Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Appoints Elina Tea to its Board of Directors
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Announces Update on its Preclinical Oncology Research Program
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Appoints Jordan Zwick to its Board of Directors
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
    From Theratechnologies
    Via GlobeNewswire
    Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
    From Theratechnologies
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.